Previous 10 |
Chief Scientific Officer Elaine Chiquette, Pharm.D., Named Among the Top 25 Women Leaders in Biotechnology Elizabeth Pash, MS, RD, LDN, Honored by Academy of Nutrition and Dietetics for Excellence in Practice Gelesis, a consumer-focused biotherapeutics company and th...
Building on the successful beta launch of its first product Plenity®, Gelesis aims to transform weight management. Gelesis developed a novel biomimetic therapeutic platform that has yielded Plenity and an advanced pipeline of therapeutic candidates for a range of other gut-rela...
Capstar Special Purpose Acquisition Corp. (NYSE:CPSR.U; CPSR; CPSR WS) (the “Company”) today announced that, as expected, on May 25, 2021 it received a notice from the New York Stock Exchange (the “NYSE”) that the Company was not in compliance with the NYSE...
News, Short Squeeze, Breakout and More Instantly...
Capstar Special Purpose Company Name:
CPSR Stock Symbol:
NYSE Market:
Capstar Special Purpose Website:
When the markets were roaring upwards in 2020 and investment capital was abundant, the number of Special Purpose Acquisition Companies (SPACs) going public broke records. Competition to find ideal companies to merge with to fulfill the SPAC’s mission, intensified. Almost two years have ...
Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as “GLS” on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 Gelesis, t...
Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing Bauerlein joins Gelesis’ board of industry ...